Each year, approximately 795,000 people experience either a new or recurrent stroke, with about 610,000 being first-time occurrences and 185,000 being recurrent attacks. In the United States, someone suffers a stroke every 40 seconds, making it a leading cause of serious long-term disability and the fifth leading cause of death.
Currently, the primary treatment for stroke involves using tissue plasminogen activator (tPA) to dissolve blood clots that obstruct blood flow to the brain.
However, a significant breakthrough in stroke treatment has emerged with Biomed's new drug, NA-911, a neuroprotective drug designed to mitigate the damage caused by stroke, as well as other hypoxic or ischemic brain injuries.
The neuroprotective effects of NA-911 are most effective when administered at a time point of 9-12 hours after the incidence of ischemia stroke, demonstrating a wide window of therapeutic opportunity.
Moreover, NA-831, a closely related analog of NA-911, has exhibited promising results in Phase 2A clinical trials for Alzheimer's disease. These results include neuroprotection and neurogenesis, which are particularly pertinent considering that stroke patients often exhibit MRI profiles similar to those seen in individuals with Alzheimer's disease.
Recent clinical investigations of NA-911 have yielded encouraging findings, including:
* No observed toxicity.
* Absence of adverse effects.
* Clean safety profile.
* Predictable pharmacokinetics.
* Excellent ability to cross the blood-brain barrier, ensuring optimal bioavailability.
NA-911 is in Phase 2 clinical trials for the treatment and prevention of stroke.
View a selected list of PUBLICATIONS and PRESENTATIONS at CONFERENCES
For further information about our research and products, please contact us.
Contact us